Because of its potential to allow for noninvasive, repetitive, and selective in vivo identification of the site and extent of apoptotic cell death and for monitoring cell death kinetics without the need for invasive biopsy, radiolabeled annexin-V is of major clinical relevance. This paper reviews available preclinical and clinical data on radiolabeled annexin-V pertaining to the domain of monitoring response to radiotherapy and chemotherapy, focusing especially on advantages and drawbacks of the different labeling procedures for the radiolabeling of annexin-V.
Radiolabeled annexin-V for monitoring treatment response in oncology / Christophe Van De, Wiele; Hubert, Vermeersch; David, Loose; Signore, Alberto; Nico, Mertens; Rudi, Dierckx. - In: CANCER BIOTHERAPY & RADIOPHARMACEUTICALS. - ISSN 1084-9785. - STAMPA. - 19:2(2004), pp. 189-194. (Intervento presentato al convegno 16th IRIST Congress on Peptide Radiopharmaceutical in Diagnosis and Therapy of Cancer and Inflammation and Infection tenutosi a Capri, ITALY nel MAY 08-10, 2003) [10.1089/108497804323071968].
Radiolabeled annexin-V for monitoring treatment response in oncology
SIGNORE, Alberto;
2004
Abstract
Because of its potential to allow for noninvasive, repetitive, and selective in vivo identification of the site and extent of apoptotic cell death and for monitoring cell death kinetics without the need for invasive biopsy, radiolabeled annexin-V is of major clinical relevance. This paper reviews available preclinical and clinical data on radiolabeled annexin-V pertaining to the domain of monitoring response to radiotherapy and chemotherapy, focusing especially on advantages and drawbacks of the different labeling procedures for the radiolabeling of annexin-V.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
